Therapy News and Research

RSS

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

TSRI scientists shed light on major toxic mechanisms of Alzheimer's disease

Scientists at The Scripps Research Institute have shed light on one of the major toxic mechanisms of Alzheimer's disease. The discoveries could lead to a much better understanding of the Alzheimer's process and how to prevent it.

11 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

Researchers may have discovered a more accurate way to predict how long patients with the deadliest form of brain cancer will live, according to an analysis by researchers from the University of Alabama at Birmingham published today in the journal PLOS ONE.

11 Apr 2013

UTHealth study explores ways to reduce infant exposure to secondhand smoke

A study to investigate whether a hospital-initiated behavioral therapy program conducted in the neonatal intensive care unit can reduce secondhand smoke in homes with infants at risk for pulmonary problems has been launched by researchers at The University of Texas Health Science Center at Houston.

11 Apr 2013

Computational simulations can help understand, treat cardiac rhythm disorders

Computational models of the human heart can be very useful in studying not just the basic mechanisms of heart function, but also to analyze the heart in a diseased state, and come up with methods for diagnosis and therapy.

11 Apr 2013

South Africa announces rollout of new single-dose ARV therapy

"South Africa's Health Minister Aaron Motsoaledi announced on Monday the launch of a new single-dose combination antiretroviral drug that will cost just 89 rand a month ($10) per patient, potentially revolutionizing AIDS treatment in the country," Salon reports (McDonough, 4/9).

11 Apr 2013

Reduction in neurogenesis associated with loss of certain cognitive faculties

These results incentivise the development of targeted therapies enabling improved neurone production to alleviate cognitive decline in the elderly and reduce the cerebral lesions caused by radiotherapy.

11 Apr 2013

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.

11 Apr 2013

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its Targeted Antibody Payload technology, disclosed for the first time today preclinical data for its EGFR-targeting ADC, IMGN289.

11 Apr 2013

Updated clinical data from phase I study of Ensituximab presented at AACR meeting

Precision Biologics announced today that in conjunction with researchers from Precsion Biologics , Johns Hopkins Medical Center and Duke University Medical Center presented updated clinical data from the phase I study of Ensituximab, a novel therapeutic antibody to treat pancreas and colorectal cancers

11 Apr 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013

Pfizer's breast cancer compound wins FDA's Breakthrough Therapy designation

Pfizer Inc. announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the United States Food and Drug Administration for the potential treatment of patients with breast cancer.

From Pfizer, Inc. 11 Apr 2013

Data on PV-10 combination therapy presented at AACR Annual Meeting

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented data on PV-10 combination therapy today at the American Association for Cancer Research Annual Meeting in Washington, DC.

11 Apr 2013

St. Jude Medical gets European CE Mark approval for deep brain stimulation systems

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its Brio, Libra and LibraXP deep brain stimulation systems for managing the symptoms of intractable primary and secondary dystonia, a neurological movement disorder that causes a person's muscles to contract and involuntarily spasm, reducing the ability to control movement.

11 Apr 2013

Research opens new avenue for treatment of melanoma

For the first time, scientists have demonstrated the mechanism of action of gossypin, a naturally-occurring substance found in fruits and vegetables, as a treatment for melanoma, which causes the majority of deaths from skin cancer.

11 Apr 2013

First-in-humans study introduces next generation cell therapy for heart failure patients

Translating a Mayo Clinic stem-cell discovery, an international team has demonstrated that therapy with cardiopoietic (cardiogenically-instructed) or "smart" stem cells can improve heart health for people suffering from heart failure.

11 Apr 2013

Finding avoids needless exposure to potentially toxic treatment

Systemic sclerosis, also known as scleroderma, is a rare autoimmune connective tissue disorder that's difficult to treat. However, thanks to new research at Northwestern University Feinberg School of Medicine and Dartmouth's Geisel School of Medicine, doctors may be able to treat some patients more effectively.

11 Apr 2013

Women who undergo surgical treatment for endometriosis have lower risk of ovarian cancer

A novel study shows women who undergo surgical treatment for endometriosis have a lower risk of developing ovarian cancer. According to results published in Acta Obstetricia et Gynecologica Scandinavica, a journal of the Nordic Federation of Societies of Obstetrics and Gynecology, hormonal treatments for endometriosis did not lower ovarian cancer risk.

11 Apr 2013

Researchers say testing for BRAF V600E-positive tumors needed for aggressive thyroid cancer

Late stage thyroid cancer patients with aggressive disease may benefit from a genetic test, but experts caution that use of this test in early stage patients is inappropriate because it is unlikely to lead to better outcomes.

11 Apr 2013

Therapy News and Research

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

TSRI scientists shed light on major toxic mechanisms of Alzheimer's disease

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

UTHealth study explores ways to reduce infant exposure to secondhand smoke

Computational simulations can help understand, treat cardiac rhythm disorders

South Africa announces rollout of new single-dose ARV therapy

Reduction in neurogenesis associated with loss of certain cognitive faculties

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

Updated clinical data from phase I study of Ensituximab presented at AACR meeting

FDA accepts Merck's NDA for NOXAFIL tablets

Pfizer's breast cancer compound wins FDA's Breakthrough Therapy designation

Data on PV-10 combination therapy presented at AACR Annual Meeting

St. Jude Medical gets European CE Mark approval for deep brain stimulation systems

Research opens new avenue for treatment of melanoma

First-in-humans study introduces next generation cell therapy for heart failure patients

Finding avoids needless exposure to potentially toxic treatment

Women who undergo surgical treatment for endometriosis have lower risk of ovarian cancer

Researchers say testing for BRAF V600E-positive tumors needed for aggressive thyroid cancer

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News